Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors
MA Guryanova, EY Chelysheva, AG Turkina - old.bloodjournal.ru
Tyrosine kinase inhibitor (TKI) therapy results in deep molecular response (MR) in 60–70%
of chronic myeloid leukemia (CML) patients. However, despite high efficacy of TKIs, many …
of chronic myeloid leukemia (CML) patients. However, despite high efficacy of TKIs, many …
[HTML][HTML] adverse events
MA Guryanova, EY Chelysheva, AG Turkina - old.bloodjournal.ru
Tyrosine kinase inhibitor (TKI) therapy results in deep molecular response (MR) in 60–70%
of chronic myeloid leukemia (CML) patients. However, despite high efficacy of TKIs, many …
of chronic myeloid leukemia (CML) patients. However, despite high efficacy of TKIs, many …
Successful use of long-term follow-up in patients with chronic myeloid leukemia with a deep molecular response at reduced doses of 2nd generation tyrosine kinase …
MA Gurianova, EY Chelysheva, OA Shukhov… - Terapevticheskii …, 2020 - ter-arkhiv.ru
Therapy with tyrosine kinase inhibitors (TKI) allows to achieve a deep molecular response in
60–70% of patients with chronic myeloid leukemia (CML). According to the current …
60–70% of patients with chronic myeloid leukemia (CML). According to the current …
Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors
Y Li, P Kuang, H Zhu, L Pan, T Dong… - Therapeutic …, 2024 - journals.sagepub.com
Background: The development of tyrosine kinase inhibitor (TKI) therapy has positively
impacted the survival rates of patients with chronic myeloid leukemia (CML). It is common in …
impacted the survival rates of patients with chronic myeloid leukemia (CML). It is common in …
Discontinuation or Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response
FX Mahon, S Saußele - Chronic Myeloid Leukemia, 2016 - Springer
Chronic myeloid leukemia (CML) is a demonstrative example of successful targeted therapy
with tyrosine kinase inhibitors (TKI). The overall survival of CML patients who respond to TKI …
with tyrosine kinase inhibitors (TKI). The overall survival of CML patients who respond to TKI …
Low‐dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment‐free remission in chronic myeloid leukemia patients: results of a …
E Cayssials, J Torregrosa‐Diaz, P Gallego‐Hernanz… - Cancer, 2020 - Wiley Online Library
Background Long‐term treatment‐free remission (TFR) represents a new goal for chronic
myeloid leukemia (CML). In clinical practice, tyrosine kinase inhibitor (TKI) dose reductions …
myeloid leukemia (CML). In clinical practice, tyrosine kinase inhibitor (TKI) dose reductions …
[HTML][HTML] Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial
F Mahon, J Richter, J Guilhot, H Hjorth-Hansen… - Blood, 2016 - Elsevier
Background: Tyrosine kinase inhibitors (TKI) have dramatically improved survival in chronic
myeloid leukemia (CML) with a high proportion of patients reaching deep molecular …
myeloid leukemia (CML) with a high proportion of patients reaching deep molecular …
Discontinuation or Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response
S Saußele, FX Mahon - Chronic Myeloid Leukemia, 2021 - Springer
Chronic myeloid leukemia (CML) is an example of successful targeted therapy with tyrosine
kinase inhibitors (TKI). The overall survival of CML patients who respond to TKI is now …
kinase inhibitors (TKI). The overall survival of CML patients who respond to TKI is now …
Russian Prospective Non-Randomized Clinical Study on Dose Reduction of Tyrosine Kinase Inhibitors with Subsequent Complete Therapy Discontinuation in Chronic …
AG Turkina, MA Gurianova, EY Chelysheva… - old.bloodjournal.ru
Background. A withdrawal of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid
leukemia (CML) patients with optimal response, especially in patients with drug toxicity, is a …
leukemia (CML) patients with optimal response, especially in patients with drug toxicity, is a …
[HTML][HTML] Treatment-Free Remission in Chronic Myeloid Leukemia
EJ Jabbour - hematologyandoncology.net
Tyrosine kinase inhibitors (TKIs) represent a major breakthrough in the treatment of chronic
myeloid leukemia (CML). Thanks to these agents, CML has been transformed from a …
myeloid leukemia (CML). Thanks to these agents, CML has been transformed from a …